Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 14/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3013428 | 1.00 | MAP2K1 (0.41) | MAP2K1SCN5ASCN9AKCNH2SRC | |
| SCHEMBL3023068 | 0.91 | SRC (0.39) | SRCMAPKAPK2 | |
| SCHEMBL3017833 | 0.91 | SRC (0.39) | SRCMAPKAPK2 | |
| SCHEMBL3531352 | 0.91 | SRC (0.39) | SRCMAPKAPK2 | |
| SCHEMBL3019404 | 0.90 | SRC (0.36) | SRCLCKKDRTEK | |
| SCHEMBL3015022 | 0.87 | NPC1 (0.42) | SRC | |
| SCHEMBL3021476 | 0.87 | MAPKAPK2 (0.44) | MAPKAPK2KDR | |
| SCHEMBL3559435 | 0.87 | MAPKAPK2 (0.44) | MAPKAPK2KDR | |
| SCHEMBL3530250 | 0.85 | MAPKAPK2 (0.37) | MAPKAPK2 | |
| SCHEMBL3529178 | 0.84 | CDK1 (0.41) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | MAP2K1 35/4885SCN5A 2705/4885SCN9A 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.